PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 57 (1) - Certificate of interest payment/Principal in case of NCD
Intimation under Regulation 57 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201521-10-2020
21-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 3571 Name of the Signatory :- Bipin SinghDesignation :- Company Secretary and Compliance Officer21-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201520-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Change in Directorate
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that at its meeting held on 14th October, 2020, the Board of Directors has, based on the recommendations of the Nomination and Remuneration Committee, appointed Mr. Suhail Nathani and Mr. Kunal Bahl as Additional Directors of the Company with effect from 14th October, 2020 to hold office as Independent Directors of the Company for a term of 5 years, subject to the approval of the shareholders. Mr. Nathani and Mr. Bahl are not related to any of the Directors of the Company. In accordance with the circular dated 20th June 2018 issued by the stock exchanges, we hereby confirm that Mr. Nathani and Mr. Bahl are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. Enclosed herewith is a press release being issued by the Company in this regards.15-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017)
Reporting of outstanding listed debt securities as on 30th September, 2020 issued on private placement basis13-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Meeting Updates
Intimation of Committee meeting pursuant to Regulations 29(3) and 50(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 201513-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Compliance Certificate Pursuant To Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations') For The Half Year Ended 30Th September, 2020
Compliance Certificate pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') for the half year ended 30th September, 202012-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201512-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201507-10-2020
PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ('SEBI Listing Regulations') And Securities And Exchange Board Of India'S Circular No. CIR/CFD/CMD/4/2015 Dated September 9, 2015
We had, vide our letter dated 27th June, 2020, made a disclosure regarding: the sale/ transfer of the pharmaceutical business ('Pharma Business') of the Company, held by the Company directly and through its subsidiaries, to Piramal Pharma Limited, wholly owned subsidiary of the Company ('PPL'); and the strategic growth investment by CA Clover Intermediate II Investments (now known as CA Alchemy Investments) ('Carlyle'), an affiliated entity of CAP V Mauritius Limited, an investment fund managed and advised by affiliated entities of The Carlyle Group Inc., for a 20% stake in the fresh equity capital of PPL (collectively referred to as 'the Transaction'). We wish to now inform you that the Transaction has successfully closed on 6th October, 2020. Enclosed herewith is a press release being issued by the Company in this regard. This is for your information and records.06-10-2020